Investors

Median Technologies appoints Dr. Yan Liu as Medical Director, Europe

24 May 2018, Sophia Antipolis, France

Press Release – For immediate release – 5:45p. CEST

Median Technologies appoints Dr. Yan Liu as Medical Director, Europe

Dr. Yan Liu will manage medical affairs, supporting the company’s clinical trials operations and business development activities in Europe

Median Technologies, the industry-leading Imaging Phenomics Company®, announced today the appointment of Dr. Yan Liu as Medical Director, Europe. Yan Liu, MD, MS, PhD, Medical Director, will be responsible for managing Medical Affairs throughout Europe, supporting Median’s clinical trials operations and business development activities.

Dr. Yan Liu is an imaging expert with more than 15 years of clinical and academic research experience. For the past 6 years, Dr. Liu has been dedicated to the integration of imaging in multicenter oncology trials and the validation of imaging biomarkers. Previously, Dr. Liu served as the head of translational research, radiotherapy and imaging department of the European Organisation for Research and Treatment of Cancer (EORTC).

Dr. Liu completed her medical studies at the Shanghai Jiaotong University College of Medicine, China, where she received her Master of Medicine in Image Diagnosis as well. Dr. Liu also studied brain functional imaging at the Erasmus Hospital in Brussels, where she earned her PhD in medical science (neuroradiology) from Université Libre de Bruxelles. Dr. Liu has published book chapters and more than 25 peer-reviewed papers in high impact journals such as Lancet Oncology and Nature Reviews Clinical Oncology.

Before joining Median, Dr. Liu was a member of the RECIST core working group, the scientific leader of two European imaging projects, and the chair for the EORTC imaging group (2016-2017).

“It is my privilege to join Median Technologies, one of the most innovative imaging phenomics companies. We have the common goal to improve patient care through high quality image analysis and management in clinical trials”, said Dr. Liu. “Cancer patient survival and quality of life can be enhanced only through medical research.  As the knowledge of cancer biology is constantly increasing, treatment options are focusing more and more on precision medicine and new strategies such as immuno-oncology. Image analysis and management, which are key for new treatment evaluation in clinical trials, today require a high level of image expertise, which is the core of Median’s activities. I am very happy to contribute to further strengthening the company’s expertise”, Dr. Liu added.

“We are thrilled to have Yan join our company. As a recognized imaging expert and researcher, she is bringing with her a very significant and unique expertise on imaging for oncology clinical trials. We are entering a new era for the pharmaceutical and healthcare industries, where Artificial Intelligence will not only play a central role in medical imaging for daily practice, but also for the discovery of non-invasive imaging biomarkers. Yan’s experience in the field is extremely valuable for our company”, said Fredrik Brag, CEO of Median Technologies.

About Median Technologies

Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions, MediScan® for Patient Care, iSee® for image management in clinical trials, ImageBank for image collection and storage during phase I studies and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need, with an eye on reducing overall care costs. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2017-2018. Median Technologies has been awarded the 2018 Tech 40 Label, has joined the EnterNext Tech 40 Index and is a winner of the Deloitte Technology Fast 500 2017 EMEA program. Median is a member of the Bpifrance Excellence Network. For more information: www.mediantechnologies.com

Contacts

Median Technologies

Emmanuelle Leygues
Sen. Dir., Corporate Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

Actifin  (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11
ggasparetto@actifin.fr

Alizé RP  (Press)

Caroline Carmagnol
Wendy Rigal
+33 1 44 54 36 66
median@alizerp.com

Cookies help us deliver our services. By using our services, you agree to our use of cookies.